Is Tilray Stock a Buy Today?

Tilray’s improving cannabis market share in Canada, positive financial growth amid macroeconomic challenges, and expanding presence in U.S. craft beer make its stock look attractive to buy on the dip.

| More on:

Shares of Tilray Brands (TSX:TLRY) have witnessed a selloff after announcing its latest quarterly financial results on October 4. Since then, the TSX-listed TLRY stock has lost nearly 9% of its value to currently trade at $2.81 per share, bringing its market cap to $2 billion and extending its year-to-date losses to 23.4%.

Before we discuss whether or not Tilray stock looks attractive to buy on the dip today, let’s take a closer look at some key highlights from its recently released quarterly earnings report.

Pot stocks are a riskier investment

Image source: Getty Images

Tilray’s first-quarter results

If you don’t know much about it already, Tilray is a New York-headquartered company that primarily focuses on selling cannabis-based consumer packaged goods and beverage alcohol to consumers. Out of its total four business segments, the company generated most of its revenue from its distribution and cannabis segments in its fiscal year 2023 (ended in May). Geographically, North America was its biggest market segment that fiscal year.

In the first quarter of its fiscal year 2024 (ended in August), Tilray’s total revenue increased by 15.5% YoY (year over year) to US$176.9 million, exceeding Street analysts’ estimate of US$173.6 million. With this, the cannabis giant’s adjusted quarterly net loss narrowed to US$55.9 million in the August 2023 quarter from US$65.8 million in the August 2022 quarter. However, its bottom line missed analysts’ estimates, who were expecting it to report a quarterly net loss of US$34.2 million. This could be one of the reasons why TLRY’s share prices slid after its earnings event, also pressuring other cannabis stocks.

These segments led its financial growth

The positive growth in the cannabis giant’s first-quarter top line could be attributed to strong sales growth numbers from its cannabis, beverage alcohol, and distribution segments. TLRY’s cannabis sales grew positively by 20.1% YoY last quarter to US$70.3 million despite facing currency headwinds, and beverage alcohol revenue grew positively by 17% from a year ago to US$24.2 million.

Breakdown of Tilray's first-quarter 2024 income statement

Similarly, its distribution sales went up by more than 14% YoY in the August quarter to US$69.2 million, as you can see in the chart above. While Tilray’s wellness segment quarterly revenue remained flat YoY on a constant-currency basis, it declined slightly to US$13.3 million due to currency headwinds.

Despite positive contributions from all business segments except cannabis, Tilray’s overall adjusted gross margin shrank to 28% last quarter from 32% a year ago. It’s important to note that the company’s cannabis segment gross margin in the August 2022 quarter benefited from the HEXO advisory fee revenue, and this advisory revenue didn’t duplicate after Tilray completed the HEXO acquisition in June 2023.

Is Tilray stock a buy today?

Despite the ongoing macroeconomic challenges, Tilray’s cannabis market share strengthened in Canada in the first quarter to 13.4%. Moreover, its overall business remains financially healthy, with continued positive growth in its revenue and profitability. For example, the company’s distribution segment profitability improved due mainly to a favourable sales mix and lower production costs.

Also, higher beer sales and its recent acquisition of Montauk Brewing Company helped it expand the beverage alcohol segment’s gross margin in the latest quarter. You can expect the segment’s profitability to keep improving in the coming quarters as Tilray recently strengthened its position in the U.S. craft beer market further by completing its acquisition of eight beer and beverage brands from Anheuser-Busch earlier this month.

Given these positive fundamental factors and expectations of stronger profits, TLRY could be a really attractive TSX stock to buy on the dip today, especially if you can hold it for the long term.

The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. Fool contributor Jitendra Parashar has no position in any of the stocks mentioned.  

More on Cannabis Stocks

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Here’s Why I Wouldn’t Touch Canopy Growth Stock With a 10-Foot Pole

Down almost 99% from all-time highs, Canopy Growth is a beaten-down cannabis stock that remains a high-risk investment in 2026.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

2 Stocks That Could Turn $100,000 Into $0 Faster Than You Think

Canopy Growth and Plug Power are two unprofitable stocks that remain high-risk investments for shareholders in 2026.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Will Canopy Growth Keep the Losing Streak Going in 2026?

Canopy Growth Corp (TSX:WEED) was one of the market's biggest losers in 2025.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

TFSA Investors: An Undervalued Cannabis Stock You Can Buy for $500 Right Now

Down almost 70% from all-time highs, Curaleaf is a TSX cannabis stock that trades at an attractive valuation in December…

Read more »